Streetbeat News

Products Services

MSOS

MariMed CEO Jon Levine highlights challenges in the cannabis industry, emphasizing the need for better consumer education on product benefits. He notes a shift in consumer perception compared to previous years.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 6:58 pm

RIO

Rio Tinto's stock is trading lower due to concerns over China's economic stimulus, impacting demand for key commodities like iron ore and copper. The Hang Seng Index's significant drop reflects investor disappointment, affecting Rio Tinto's revenue outlook.

Portfolio Pulse from Henry Khederian

October 08, 2024 | 6:56 pm

MSOS

iAnthus CEO Richie Proud emphasizes the importance of emotional connection between brands and consumers, highlighting the need for effective storytelling. He advises companies to consider the role of their products in consumers' lives and balance consumer retention with new consumer acquisition.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 6:54 pm

AYRWF

MSOS

Jamie Mendola from Ayr Wellness highlights the increasing sophistication in consumer inquiries within the cannabis industry. This trend reflects a maturing market and could influence companies like Ayr Wellness and ETFs such as MSOS.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 6:51 pm

MRMD

MariMed's CEO Jon Levine emphasizes the company's focus on precision dosing and consistency to enhance customer comfort with their brand. The company has conducted research on both the wholesale and consumer sides to better educate and reach customers.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 6:50 pm

SMCI

Super Micro Computer Inc. (NASDAQ:SMCI) experienced a volatile stock movement after announcing the shipment of over 100,000 GPUs per quarter, potentially generating billions in revenue. Despite a 15% initial surge, the stock fell by 7% amid concerns over sustainability and ongoing legal investigations. The company faces challenges with technical indicators showing bearish signals, although short-term bullish potential exists.

Portfolio Pulse from Surbhi Jain

October 08, 2024 | 6:48 pm

TVGN

Tevogen Bio's trial data for TVGN 489 shows no dose-limiting toxicities or significant adverse events. The study met its endpoints on safety, viral load reduction, and anti-COVID-19 responses. 50% of patients were immunocompromised and infected with SARS-CoV-2 variants. All treated patients returned to baseline health within 14 days and showed no long COVID or reinfection at six-month follow-up. The CEO is advocating for patient support and pledges to use assets to combat long COVID and drive medical innovation.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 6:42 pm

LLY

NVO

The potential expansion of obesity drug coverage could increase healthcare spending by $35 billion through 2034. This development may impact pharmaceutical companies involved in obesity treatments.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 6:26 pm

CURLF

NKE

Curaleaf Holdings Inc's CEO Boris Jordan discusses the company's progress and future plans at the Benzinga Cannabis Capital Conference. He highlights Curaleaf's cost-cutting measures, European expansion, and the challenges in the cannabis market, including hemp proliferation and economic pressures.

Portfolio Pulse from Adam Eckert

October 08, 2024 | 6:19 pm

MDXXF

PharmAla Biotech Holdings Inc. (OTC:MDXXF) will supply the University of Texas, San Antonio with a novel MDMA dosage form for a clinical trial. The company also announced a new patent application for its APA-01 molecular entity.

Portfolio Pulse from Juan Spínelli

October 08, 2024 | 6:14 pm